Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

s and the potential to generate near-term revenue through product sales or royalties for the approved indications in China while seeking global approval in new indications.

DelMar will continue the business of DelMar Pharmaceuticals (BC) Ltd., headquartered in Vancouver, British Columbia with clinical operations in Menlo Park, CA, as a subsidiary under the leadership of DelMar Pharmaceuticals (BC) Ltd.'s current management team, headed by Chief Executive Officer Jeffrey Bacha . In connection with the Acquisition, DelMar issued to the former shareholders of DelMar Pharmaceuticals (BC) Ltd. the equivalent of 13,070,000 shares of its common stock.  Details of the transaction will be filed on a Form 8-K with the United States Securities and Exchange Commission.

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be resold absent registration under or exemption from such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... 2014 Shimadzu Scientific Instruments has ... and highly precise tool for measuring displacement in ... With 1000-mm maximum movement distance, the DSES-1000 can ... gauge length of 10 mm. In addition, it ... 50-mm stroke and within +/- 100 µm below ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
(Date:9/30/2014)... CORD:USE Cord Blood Bank – www.corduse.com ... entered into an Equity and Exclusive Services Agreement with ... of patented technologies for the isolation of human cord ... is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that the ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... CSA Medical, Inc. ( www.CSAmedical.com ... technology and business plans for its proprietary spray ... Medical will be one of only eleven companies ... companies in total will present across three categories. ...
... health care startups reported $572 million in total investments ... 2010, according to the BioEnterprise Midwest ... year, while the total dollar ... of companies financed remains the same.   ...
... SAN DIEGO, Oct. 28 Orexigen® Therapeutics, Inc. (Nasdaq: ... of obesity, will announce financial results for the third quarter ... markets close. The announcement will be followed by a live ... Orexigen management will host the call and webcast ...
Cached Biology Technology:CSA Medical Selected to Present at Mid-Atlantic Bio Conference 2Midwest Health Care Startups Raise $572 Million Through Q3 2010 2Midwest Health Care Startups Raise $572 Million Through Q3 2010 3
(Date:9/29/2014)... A new study confirms that the exposure to tar ... than of regular cigarettes. Similarly, exposure to nicotine ... increasingly popular type of cigarette in several countries around ... of certain toxic chemicals in the smoke of these ... because lower levels of chemicals in the smoke are ...
(Date:9/29/2014)... NASA story from 2009, "human activities in this area of ... Palm oil is increasingly grown for use as a cooking ... foods. It has become the most widely produced edible oil ... to surpass that of soybean oil. , The environmental effects ... cleared to grow the crop, and the preferred method is ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... the Science of Food and Agriculture shows that konjac ... strains of E. coli and Salmonella bacteria. The study ... Research Centre, the Netherlands, shows that these foodstuffs act as ... themselves to the fibrous foods instead of the gut cells ...
... an ice-free region of Antarctica have discovered the last ... insects--on the interior of the southernmost continent before temperatures ... An abrupt and dramatic climate cooling of 8 degrees ... roughly 14 million years ago, forced the extinction of ...
... (August 5, 2008) A study published online today in ... two eggs for breakfast, as part of a reduced-calorie diet, ... than those who eat a bagel breakfast of equal calories. ... Journal of the American College of Nutrition , which ...
Cached Biology News:Antarctic fossils paint a picture of a much warmer continent 2Antarctic fossils paint a picture of a much warmer continent 3Antarctic fossils paint a picture of a much warmer continent 4Antarctic fossils paint a picture of a much warmer continent 5Adults who eat eggs for breakfast lose 65 percent more weight 2Adults who eat eggs for breakfast lose 65 percent more weight 3
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... The membrane filters suitable for use in ... on top of each filter, in a specially ... ,The special pleating of the band of membrane ... when dispensed. The shape of the sealed band ...
... [RS17 ] to PRKAR2 cAMP is ... of cellular functions. cAMP exerts its effects ... which transduces the signal through phosphorylation of ... AMPK is a tetramer composed of two ...
Biology Products: